Cited by 20MicroRNA in disease regulationHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathology

p65/miR‐23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma

Open access
Li, Zhi‐Qin, Wang, Hong‐Yan, Zeng, Qing‐Lei, Yan, Jing‐Ya, Hu, Yu‐Shu, Li, Hua, Yu, Zu‐Jiang·2020·Cancer Medicine

Abstract

Background: CCL22 played critical roles in Tregs recruitment. The upstream regulators modulating CCL22 in hepatocellular carcinoma (HCC) were not clearly understood. Methods: MiR‐23a, p‐p65, p65, CCL22, and Foxp3 levels were monitored by RT‐qPCR and western blotting. Immunofluorescence assay was used to perform the costaining of Foxp3 and CD4 on liver tissues. Transwell assay was applied to evaluate the migration ability of Tregs. Dual‐luciferase assay was performed to determine relationship of miR‐23a/CCL22 and p65/miR‐23a. Chromatin immunoprecipitation (ChIP) was applied to detect the direct binding of p65 to miR‐23a promoter. Xenograft tumor models were developed to investigate the functions of p65 and miR‐23a in vivo. Results: HBV infection was associated with reduced survival and increased Tregs recruitment in HCC patients. MiR‐23a was decreased, whereas p65, CCL22, and Foxp3 were increased in HBV+ tumors. MiR‐23a was inversely correlated with CCL22 and Foxp3 expression in HCC. MiR‐23a directly targeted CCL22 3’UTR, leading to CCL22 reduction and attenuated Tregs recruitment. Meanwhile, p65 functioned as a transcription repressor of miR‐23a by directly binding to its promoter. Inhibition of p65 induced miR‐23 expression, leading to less CCL22 expression and Tregs recruitment in vitro. CCL22 was the indispensable effector underlying p65/miR‐23a axis and Tregs recruitment. MiR‐23a inhibitor promoted xenografted tumor growth accompanying with upregulation of CCL22, whereas p65 inhibition exerted opposite effects. Conclusion: Blockage of p65 disinhibited miR‐23a expression, leading to CCL22 reduction and repress Tregs recruitment. Targeting p65/miR‐23a/CCL22 axis was a novel approach for HBV+ HCC treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.2611

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In HBV-infected HCC patients, miR-23a is decreased and target gene CCL22 is increased.

    “miR-23a decreased in HCC patients infected with the hepatitis B virus, along with an increase in the target gene CCL22.”
  • miR-23a inhibitors promote tumor growth by upregulating CCL22 on the p65/miR-23a/CCL22 axis to regulate T cell recruitment in HBV-positive HCC.

    “The use of miR-23a inhibitors promotes tumor growth by upregulating target gene CCL22 on the p65/miR-23a/CCL22 axis to regulate T cell recruitment in hepatitis B virus positive HCC [74,75].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 27 · Cited by 20

Authors
Li, Z., Wang, H., Zeng, Q., Yan, J., Hu, Y., Li, H., & Yu, Z.
Affiliations
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Department of Infectious Disease The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan P.R. China
Corresponding author
  • Li, Zhi‐Qin
  • Yu, Zu‐Jiang
Venue
Cancer Medicine
Publisher
Wiley
Published
2019-11-25
Volume
9
Issue
2
Pages
711-723
ISSN
2045-7634 (ISSN-L)
OpenAlex
W2989827657
Cited by
20
References
27
Citations by year
2026: 1 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 2 · 2020: 1
FWCI
0.47
Type
journal article
Language
en
Open access
Locations
  • Cancer Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Science and Technology Department of Henan Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
hepatocellular carcinoma, hepatitis B virus, regulatory T cells, CCL22, miR-23a, NF-κB p65, Foxp3, tumor immune microenvironment, Treg recruitment, microRNA target regulation, tumor growth
MeSH terms
Animals, Female, Hepatitis B, Hepatitis B virus, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Mice, Inbred BALB C, Mice, Nude, Middle Aged, Prognosis, Tumor Cells, Cultured, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Apoptosis, Xenograft Model Antitumor Assays, MicroRNAs, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Transcription Factor RelA, Chemokine CCL22

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review